Ginkgo Bioworks Holdings, Inc. ( (DNA) ) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ginkgo Bioworks Holdings, Inc. is a biotechnology company specializing in the development of tools and technologies to make biology easier to engineer, focusing on sectors such as therapeutics, diagnostics, and manufacturing. The company also offers biosecurity solutions to address biological threats.
In its third quarter of 2025 financial report, Ginkgo Bioworks announced a total revenue of $39 million, marking a 56% decrease from the previous year, primarily due to a significant non-cash revenue in the prior year. The company reported a GAAP net loss of $81 million and an adjusted EBITDA of negative $56 million, reflecting challenges in maintaining revenue growth.
Key financial metrics revealed a decline in both Cell Engineering and Biosecurity revenues, with the former dropping to $29 million from $75 million and the latter to $9 million from $14 million year-over-year. Despite these setbacks, Ginkgo Bioworks highlighted strategic partnerships, including an extended collaboration with Bayer in agricultural biologicals and a new project with BARDA to advance monoclonal antibody biomanufacturing.
Ginkgo’s strategic focus on AI-enabled cloud lab technology positions it to leverage AI models in biotechnology, aiming to enhance lab automation and biological discovery. The company is expanding its autonomous lab capabilities in Boston, showcasing its commitment to innovation and scientific advancement.
Looking forward, Ginkgo Bioworks maintains its full-year 2025 revenue outlook, expecting total revenue between $167 million and $187 million. The company remains optimistic about its strategic partnerships and technological advancements, aiming to sustain its role at the forefront of the bioeconomy.